A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier

Cancer Research

Volumn 59, Issue 10, 1999, Pages 2411-2416

  Hendrikse, N Harry ^a   De Vries, Elisabeth G E ^a   Eriks Fluks, Lizette ^a   Van Der Graaf, Winette T A ^a   Hospers, Geke A P ^a   Willemsen, Antoon T M ^a   Vaalburg, Willem ^a   Franssen, Eric J F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DAUNORUBICIN; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL SURVIVAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; NEWBORN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT; TUMOR;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOOD-BRAIN BARRIER; BRAIN CHEMISTRY; CALCIUM CHANNEL BLOCKERS; CARCINOMA, SMALL CELL; CYCLOSPORINE; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS; P-GLYCOPROTEIN; RATS; RATS, NUDE; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0033563120     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Endicott, J. A., and Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem., 58: 137-171, 1989.
2. Gottesman, M. M., and Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62: 385-427, 1993.
3. Zamora, J. M., Pearce, H. L., and Beck, W. T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol. Pharmacol., 33: 454-462, 1988.
4. Klopman, G., Srivastava, S., Kolossvary, I., Epand, R. F., Ahmed, N., and Epand, R. M. Structure-activity study and design of multidrug-resistant reversal compounds by a computer automated structure evaluation methodology. Cancer Res., 52: 4121-4129, 1992.
5. Selassie, C. D., Hansch, C., and Khwaja, T. A. Structure-activity relationships of antineoplastic agents in multidrug resistance. J. Med. Chem., 33: 1914-1919, 1990.
6. Germann, U. A., Pastan, I., and Gottesman, M. M. P-glycoproteins: mediators of multidrug resistance. Semin. Cell. Biol., 4: 63-76, 1993.
7. Doige, C. A., and Ames, G. F. ATP-dependent transport systems in bacteria and humans: relevance to cystic fibrosis and multidrug resistance. Annu. Rev. Microbiol., 47: 291-319, 1993.
8. Schinkel, A. H., and Borst, P. Multidrug resistance mediated by P-glycoproteins. Semin. Cancer Biol., 2: 213-226, 1991.
9. Sonneveld, P., Schoester, M., and de Leeuw, K. Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J. Clin. Oncol., 12: 1584-1591, 1994.
10. Sonneveld, P., Durie, B. G., Lokhorst, H. M., Marie, J. P., Solbu, G., Suciu, S., Zittoun, R., Lowenberg, B., and Nooter, K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet, 340: 255-259, 1992.
11. Grunicke, H., and Hofmann, J. Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level. Pharmacol. Ther., 55: 1-30, 1992.
12. Brunton, V. G., and Workman, P. Cell-signaling targets for antitumour drug development. Cancer Chemother. Pharmacol., 32: 1-19, 1993.
13. Wilson, W. H., Bates, S. E., Fojo, A., Bryant, G., Zhan, Z., Regis, J., Wittes, R. E., Jaffe, E. S., Steinber, S. M., Herdt, J., and Chabner, B. A. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J. Clin. Oncol., 13: 1995-2004, 1995.
14. Wilson, W. H., Jamis-Dow, C., Bryant, G., Balis, F. M., Klecker, R. W., Bates, S. E., Chabner, B. A., Steinberg, S. M., Kohler, D. R., and Wittes, R. E. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J. Clin. Oncol., 13: 1985-1994, 1995.
15. Abe, T., Koike, K., Ohga, T., Kubo, T., Wada, M., Kohno, K., Morie, T., Hidaka, K., and Kuwano, M. Chemosensitisation of spontaneous multidrug resistance by a 1,4-dihydropyridine analogue and verapamil in human glioma cell lines overexpressing MRP or MDR1. Br. J. Cancer, 72: 418-423, 1995.
16. Schinkel, A. H., Wagenaar, E., Van Deemter, L., Mol, C. A. A. M., and Borst, P. Presence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest., 96: 1698-1705, 1995.
17. Hendrikse, N. H., Schinkel, A. H., De Vries, E. G. E., Fluks, E., Van der Graaf, W. T. A., Vaalburg, W., and Franssen, E. J. F. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br. J. Pharmacol., 124: 1413-1418, 1998.
18. Schinkel, A. H., Wagenaar, E., Mol, C. A. A. M., and Van Deemter, L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest., 97: 2517-2524, 1995.
19. Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J. J., and Roden, D. M. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest., 110: 289-294, 1998.
20. Mayer, U., Wagenaar, E., Dorobek, B., Beijnen, J. H., Borst, P., and Schinkel, A. H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest., 100: 2430-2436, 1997.
21. Hughes, C. S., Vaden, S. L., Manaugh, C. A., Price, G. S., and Hudson, L. C. Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats. J. Neuro-Oncol., 37: 45-54, 1998.
22. Van der Graaf, W. T. A., Buter, J., De Vries, E. G. E., Willemse, P. H. B., Sleijfer, D. T., and Mulder, N. H. High dose oral amiodarone added to doxorubicin and vindesine for overcoming multidrug resistance in solid tumors. Annu. Oncol., 5: 659-663, 1994.
23. Bates, S. E., Meadows, B., Goldspiel, B. R., Denicoff, A., Le, T. B., Tucker, E., Steinber, S. M., and Elwood, L. J. A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer. Cancer Chemother. Pharmacol., 35: 457-463, 1995.
24. Barbaris, E., Kronauge, J. F., Cohen, D., Davison, A., Jones, A. G., and Croop, J. M. Characterization of P-glycoprotein transport and inhibition in vivo. Cancer Res., 58: 276-282, 1998.
25. Piwnica-Worms, D., Chiu, M. L., Budding, M., Kronauge, J. F., Kramer, R. A., and Croop, J. M. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res., 53: 977-984, 1993.
26. Crankshaw, C. L., Marmion, M., Luker, G. D., Rao, V., Dahlheimer, J., Burleigh, D., Webb, E., Deutsch, K. F., and Piwnica-Worms, D. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein. J. Nucl. Med., 39: 77-86, 1998.
27. Luker, G. D., Rao, V. V., Crankshew, C. L., Dahlheimer, J., and Piwnica-Worms, D. Characterization of phosphine complexes of technetium (III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier. Biochemistry, 36: 14218-14227, 1997.
28. 99mTechnetium-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J. Nucl. Med., 37: 1578-1582, 1996.
29. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance associated protein. Br. J. Cancer, 77: 353-358, 1998.
30. 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. Eur. J. Biochem, 252: 140-146, 1998.
31. 11C]-Labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. J. Nucl. Med., 37: 1571-1575, 1996.
32. Boesen, J. J. B., Nooter, K., and Valerio, D. Circumvention of chemotherapy-induced myelosuppression by transfer of the MDR1 gene. Biotherapy, 6, 291-302, 1994.
33. Timmer-Bosscha, H., Hospers, G. A. P., Meijer, C., Mulder, N. H., Muskiet, F. A., Martini, I. A., Uges, D. A., and De Vries, E. G. E. Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J. Natl. Cancer Inst., 81: 1069-1075, 1989.
34. Flens, M. J., Izquierdo, M. A., Scheffer, G. L., Fritz, J. M., Meijer, C. J., Scheper, R. J., and Zaman, G. J. R. Immunohistochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res., 54: 4557-4563, 1994.
35. Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Van der Valk, M. A., Robanus-Maandag, E. C., Te Riele, H. P. J., Berns, A. M. J., and Borst, P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 77: 491-502, 1994.
36. 3H-colchicine. J. Nucl. Med., 33: 1373-1377, 1992.
37. 14C]-colchicine for identification of tumor multidrug resistance. J. Nucl. Med., 35: 1179-1184, 1994.
38. 14C]-colchicine biodistribution with whole-body quantitative autoradiography in colchicine-sensitive and -resistant xenografts. J. Nucl. Med., 37: 312-314, 1996.
39. 1), in human cancer cell lines. Cancer Res., 57: 3537-3547, 1997.
40. Lankelma, J., Spoelstra, E. C., Dekker, H., and Broxterman, H. J. Evidence for daunomycin efflux from multidrug-resistant 2780AD human ovarian carcinoma cells against a concentration gradient. Biochim. Biophys. Acta, 1055: 217-222, 1990.
41. Spoelstra, E. C., Westerhoff, H. V., Dekker, H., and Lankelma, J. Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells. Eur. J. Biochem., 207: 567-579, 1992.
42. 99mTc-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl. Med. Commun., 16: 253-257, 1995.
43. 99mTc-Sestamibi in vivo. J. Nucl. Med., 38: 369-372, 1997.
44. 99mtechnetium-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J. Nucl. Med., 38: 1348-1351, 1997.